United States· US:0310-4500_686baf25-364f-4124-858f-151f1dae3756
IMFINZI
A medicinal product containing durvalumab, registered in United States by AstraZeneca Pharmaceuticals LP.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- Durvalumab
- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc1103104500121 VIAL in 1 CARTON (0310-4500-12) / 2.4 mL in 1 VIAL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Durvalumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainIMFINZI 50 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONAstrazeneca Ab
- FinlandImfinzi2care4 ApS
- BelgiumImfinzi 50 mg/mlAstraZeneca
- SwitzerlandImfinzi
- CzechiaIMFINZIAstraZeneca AB, Södertälje
- United KingdomImfinzi 120mg/2.4ml concentrate for solution for infusion vialsAstraZeneca UK Ltd
- Japanデュルバルマブ（遺伝子組換え）アストラゼネカ
- IrelandIMFINZI 50 mg/ml concentrate for solution for infusion.AstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imfinzi
- Liechtenstein · Imfinzi
- Norway · Imfinzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6c32026f-0e95-4d9a-a53f-4dd86e6f018f GET /v1/drugs/6c32026f-0e95-4d9a-a53f-4dd86e6f018f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 2
},
"productid": "0310-4500_686baf25-364f-4124-858f-151f1dae3756",
"productndc": "0310-4500",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "DURVALUMAB",
"proprietary_name": "IMFINZI",
"active_ingred_unit": "mg/2.4mL",
"application_number": "BLA761069",
"marketing_category": "BLA",
"nonproprietary_name": "Durvalumab",
"start_marketing_date": "20170501",
"active_numerator_strength": "120"
}See everything about durvalumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.